# NiKang Therapeutics

> Clinical-stage biotechnology company in Wilmington, Delaware, founded 2017, discovering small
> molecule oncology medicines against difficult-to-drug targets — HIF2alpha, CDK2, CDK2/4 and KRAS
> G12D — using structure-based drug design across both inhibitor and targeted-protein-degradation
> modalities.

NiKang Therapeutics runs no developer program. It publishes no product API, no developer portal, no
API reference and no machine-readable specification of its own. https://www.nikangtx.com/llms.txt
returns 404; this file is an API Evangelist generation, not a NiKang publication.

The only machine-readable surface reachable without credentials is the WordPress REST content API at
https://www.nikangtx.com/wp-json — 210 registered routes across 17 namespaces, of which the
anonymously readable read-only content families are described in this repository's openapi/ directory.
It is free, needs no key, and returns JSON.

## What you can actually call

Base URL: https://www.nikangtx.com/wp-json — no authentication, no signup, no quota.

- Search everything: `GET /wp/v2/search?search=<term>&subtype=any` — the only cross-type call.
- News archive: `GET /wp/v2/posts` — 16 published posts (press releases, clinical data, presentations).
- Corporate pages: `GET /wp/v2/pages` — 9 pages including science-and-pipeline and about-us.
- Board and officers: `GET /wp/v2/dt_team` — 10 people, categorised Board (7) / Officers (2).
- Media assets: `GET /wp/v2/media` — 67 attachments with direct source_url values.
- Categories: `GET /wp/v2/categories` — 3 registered; only `news` (16 posts) is non-empty.
- Route index: `GET /wp-json` — the full self-describing 210-route table.

Paginate with `page` and `per_page` (max 100 — 101 or more returns HTTP 400, it is not clamped).
Read totals from the `X-WP-Total` and `X-WP-TotalPages` response headers. Trim payloads with
`_fields`, inline related objects with `_embed`.

Errors are the WordPress envelope `{code, message, data:{status}}` as application/json — NOT RFC 9457
problem+json. Branch on `code`, never on `message`.

There are no rate-limit headers. Send a real browser User-Agent, honour the `Crawl-delay: 10` in
robots.txt, and respect the advertised `max-age=600` cache window — a non-browser User-Agent was served
a Cloudflare HTML challenge during profiling. If a response body is HTML, it is an edge challenge, not
an API error: the WordPress envelope always carries a `code` field.

`/wp/v2/users` returns 401, so the integer `author` id on a post cannot be resolved to a name. Use
`/wp/v2/dt_team` for NiKang's named people instead.

## Company

- Website: https://www.nikangtx.com/
- About us: https://www.nikangtx.com/about-us/
- Science & Pipeline: https://www.nikangtx.com/science-and-pipeline/
- News: https://www.nikangtx.com/news/ (RSS: https://www.nikangtx.com/feed/)
- Careers: https://www.nikangtx.com/careers/
- Jobs: https://www.nikangtx.com/jobs/
- Privacy Policy: https://www.nikangtx.com/privacy-policy-statement/
- Terms of Use: https://www.nikangtx.com/terms-of-use/
- LinkedIn: https://www.linkedin.com/company/nikang-therapeutics-inc
- Headquarters: 200 Powder Mill Road, Building E500, Wilmington, DE 19803
- General enquiries: info@nikangtx.com — this is not a developer support channel.

## Pipeline

- NKT2152 — orally bioavailable allosteric HIF2alpha inhibitor. Phase 1/2 in clear cell renal cell
  carcinoma, VHL disease and other solid tumours.
- NKT3964 — first-in-class selective CDK2 degrader. Phase 1 in advanced or metastatic solid tumours.
- NKT5097 — first-in-class dual CDK2/4 degrader. Phase 1 in advanced or metastatic solid tumours.
- KRAS G12D — small molecule programme in discovery / IND-enabling work.

Partnerships: Erasca (SHP2, 2020), Pfizer (HIF2, 2021), Hansoh (HIF2, 2022), Roche (HIF2, 2023).
Funding: $10M Series A (Dec 2017), $50M Series B (Sep 2020), $200M Series C (May 2021).

## Machine-readable artifacts in this profile

- openapi/ — nine derived OpenAPI 3.2.0 documents, 26 operations
- overlays/nikang-therapeutics-content-overlay.yaml — what API Evangelist added on top of the route index
- authentication/nikang-therapeutics-authentication.yml — anonymous read; the 401 boundary
- conventions/nikang-therapeutics-conventions.yml — pagination, errors, caching, reversibility (na)
- errors/nikang-therapeutics-problem-types.yml — 7 error codes captured live
- data-model/nikang-therapeutics-data-model.yml — 10 entities, 11 relationships
- conformance/nikang-therapeutics-conformance.yml — oEmbed 1.0, RFC 8288, sitemaps 0.9 confirmed
- lifecycle/nikang-therapeutics-lifecycle.yml — no versioning policy, no SLA, no status page
- rate-limits/nikang-therapeutics-rate-limits.yml — limit_count 0; the edge control is unsignalled
- plans/nikang-therapeutics-plans-pricing.yml — plan_count 0; nothing is for sale
- packages/nikang-therapeutics-packages.yml — no SDKs; npm/PyPI/GitHub all probed empty
- mcp/nikang-therapeutics-mcp.yml — no MCP server exists; a candidate tool list only
- well-known/nikang-therapeutics-well-known.yml — every /.well-known path 404s on both hosts
- security/nikang-therapeutics-domain-security.yml — TLS 1.3, no HSTS, no CAA, DMARC p=reject
- skills/ — three Agent Skills grounded in real operationIds

## Not present

No OpenAPI published by NiKang. No GraphQL, no gRPC, no SOAP/WSDL, no AsyncAPI, no webhooks, no
events. No MCP server. No A2A agent card — every /.well-known/agent-card.json and
/.well-known/agent.json probe returned 404. No SDKs, no CLI, no Postman collection, no GitHub
organisation. No status page, no changelog, no deprecation policy, no SLA. No pricing and no plans.